Navigation Links
Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities
Date:5/18/2012

e expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Oncology's future results, levels of activity, performance or achievements may not meet these expectations.  The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Oncology's expectations, except as required by law.

CONTACT: Joel Ackerman, +1-201-808-8400


'/>"/>
SOURCE Champions Oncology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
2. Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand Its Personalized Oncology Business
3. Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing
4. Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
5. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
6. Champions Biotechnology to Present at Rodman & Renshaws Eleventh Annual Healthcare Conference
7. Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement
8. Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
9. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
10. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
11. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 Gallus BioPharmaceuticals , ... and manufacturing organization (CMO) announced today that it ... oncology company focused on the development of innovative ... the anti-prostate specific membrane antigen (PSMA) monoclonal antibody ... Under the agreement the antibody will be produced ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 On Wednesday of ... gel to use Redox Signaling molecules, became available for purchase ... overwhelming. , "The way that RENU 28 works is, if ... slowing down of the rate of cellular renewal within your ... the increasing of that rate of cellular renewal. What RENU ...
(Date:8/20/2014)... inventions licensed to biotechnology firms has revealed early ... these roadblocks, the researchers suggest that better communication ... could lead to faster commercialization down the road. ... made in university laboratories and licensed to biotechnology ... which have a high failure rate. But a ...
(Date:8/20/2014)... For the first time, chemists have succeeded in measuring ... time resolution. The study reveals how vibration of a ... groups. , The study was performed at the ... from the University of Jyvskyl works as a visiting ... in the study. The second team was lead by ...
Breaking Biology Technology:Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3RENU 28 Skin Care Now Available in Australia and New Zealand 2Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3Seeing a molecule breathe 2
... , SHANGHAI, Nov. 24 /PRNewswire-Asia/ ... (SFDA) has approved the,investigational new drug application (IND) for its ... This IND,approval allows Biolaxy to initiate its first phase I ... disorder characteristic of high blood glucose and poor,metabolism. The complications ...
... Primary efficacy endpoint has been met for ... , QUEBEC CITY, Nov. 24 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. ... biopharmaceutical company focused on endocrine therapy and oncology, today announced ... targeted cytotoxic peptide conjugate, AEZS-108 (formerly AN-152), in patients with ...
... DIEGO, Nov. 24, 2009 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ... present at the Piper Jaffray 21st Annual Health Care Conference on ... Time) at the New York Palace Hotel in New York City. ... provide an overview of the company, including its clinical development and ...
Cached Biology Technology:Biolaxy Secures IND Approval for Oral Insulin 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 3
(Date:8/21/2014)... Mller the Fram Strait is a key region in the ... between Greenland and Svalbard warm Atlantic water flows to the ... cold Arctic water masses and sea ice push their way ... portion of the Atlantic water cools here on its way ... of the water caused in this manner drives the global ...
(Date:8/21/2014)... Wednesday, Oct. 18-22, 2014 , WHERE: , ... San Diego, CA 92101 , WHAT: , ... of the latest research in human genetics. Examples ... high-scoring abstracts on rare genetic variants in health ... treatment for sun sensitivity (Saturday, Oct. 18, 5:30-7:30 ...
(Date:8/21/2014)... feeding tube connectors, designed by an international standards process, ... , According to an invited review published in the ... ( NCP ), the official journal of the American ... connectors will greatly reduce the occurrence of misconnection that ... Small-bore connectors, which are used to join medical devices, ...
Breaking Biology News(10 mins):Arctic sea ice influenced force of the Gulf Stream 2Arctic sea ice influenced force of the Gulf Stream 3American Society of Human Genetics 2014 Annual Meeting 2New feeding tube connectors will improve patient safety 2
... review of the principles and management implications of nitrogen ... new monograph Nitrogen in Agricultural Systems . The ... Crop Science Society of America (CSSA), and the Soil ... 30 leading experts to holistically address nitrogen in the ...
... biomedical engineering assistant professor at The University of ... million National Institutes of Health/National Cancer Institute grant ... James Tunnell says the five-year project will include ... Anderson Cancer Center in Houston and the University ...
... In a move that promises to change the economics of ... set of techniques for cleanly converting problematic biofuels waste into ... available online in the journal Metabolic Engineering . The ... new fermentation process that allows E. coli and ...
Cached Biology News:Nitrogen: Nutrient of life 2Research yields pricey chemicals from biodiesel waste 2Research yields pricey chemicals from biodiesel waste 3
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. Mfr ...
A cost-effective serum for general cell growth requirements. All serum is collected from calves aged 10 days old or less....
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... cell culture scale-up, these culture chambers produce ... 10 9 range and are useful ... flasks. • High mechanical • strength and ... to shipping • Certified nonpyrogenic and sterilized ...
Biology Products: